Here are five key notes:
1. KOVANAZE is the first product developed by the Fort Collins, Colo.-based company St. Renatus.
2. Traditionally, the dental industry has used needle injected anesthetic. However, KOVANAZE is administered through a nasal spray, without the use of a needle.
3. KOVANAZE contains tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The nasal spray is a topical, tooth nerve anesthetic, developed for dental procedures involving the upper teeth.
5. St. Renatus specifies that the anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.
More articles on anesthesia:
MIT and Massachusetts General Hospital develop sensor for anesthesiologists: 5 takeaways
Medaxion raises $950k in financing: 4 notes
Sweet Dreams Nurse Anesthesia settles False Claims allegations for $1M+: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.